4 days ago · ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ …

Apr 22, 2024 · FDA approves ImmunityBio's ANKTIVA, a groundbreaking IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Learn more today!

Jan 15, 2025 · ImmunityBio plans to submit a Biologics License Application (BLA) in 2025 for second- and third-line treatment of patients with NSCLC, who are progressing on checkpoint …

Explore ImmunityBio's pipeline to find information on our clinical trials. We have immunotherapy trials in various stages focusing on a variety of diseases.

Dec 10, 2024 · ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by …

Jan 2, 2024 · ImmunityBio is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell …

ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious disease. Since then we have progressed into a clinical …

ImmunityBio works every day to develop immunotheraphies that deliver better outcomes for cancer patients. Visit our website to learn more about our novel investigational immunotherapy …

Aug 12, 2024 · ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Oct 24, 2024 · “This trial is important for ImmunityBio as our first clinical study of our CAR-NK, CD19 t-haNK cell line, as well as one of our first studies in liquid tumors,” said Patrick Soon …